| Chhaya J Gandhi, PA-C | |
|
1365 Clifton Rd Ne, Suite A 4325, Atlanta, GA 30322-1059 | |
| (404) 778-3914 | |
| Not Available |
| Full Name | Chhaya J Gandhi |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 14 Years |
| Location | 1365 Clifton Rd Ne, Atlanta, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003112236 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363AM0700X | Physician Assistant - Medical | 006046 (Georgia) | Secondary |
| 208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | 6046 (Georgia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Emory Clinic, Inc | 8820901408 | 2687 |
| Wellstar Medical Group, Llc | 6709065402 | 1839 |
News Archive
Barbara Feigin, successful business owner and breast cancer survivor, wanted to find a unique and memorable way to honor other breast cancer survivors and those who have fallen to the disease so she decided to paint the 44,000 square-foot administrative building at her company MainStreet America pink.
A study by UCLA researchers is the first to demonstrate a technique for coaxing pluripotent stem cells - which can give rise to every cell type in the body and which can be grown indefinitely in the lab - into becoming mature T cells capable of killing tumor cells.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced that the company has commenced enrollment in a Phase 2 clinical trial of IMO-8400, an investigational TLR 7, 8 and 9 antagonist, in patients with dermatomyositis. Dermatomyositis is a rare and debilitating inflammatory muscle and skin disease associated with significant morbidity, decreased quality of life and an increased risk of premature death.
Hythiam, Inc. announced today that the results of a double-blind, placebo-controlled study on the impact of the medical component of the PROMETA® Treatment Program on alcohol dependent subjects was accepted and published in the Journal of Clinical Psychopharmacology, a leading scholarly publication in psychopharmacology that features articles reporting on clinical trials and studies.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Chhaya J Gandhi, PA-C 1365 Clifton Rd Ne, Suite A 4325, Atlanta, GA 30322-1059 Ph: (404) 778-3914 | Chhaya J Gandhi, PA-C 1365 Clifton Rd Ne, Suite A 4325, Atlanta, GA 30322-1059 Ph: (404) 778-3914 |
News Archive
Barbara Feigin, successful business owner and breast cancer survivor, wanted to find a unique and memorable way to honor other breast cancer survivors and those who have fallen to the disease so she decided to paint the 44,000 square-foot administrative building at her company MainStreet America pink.
A study by UCLA researchers is the first to demonstrate a technique for coaxing pluripotent stem cells - which can give rise to every cell type in the body and which can be grown indefinitely in the lab - into becoming mature T cells capable of killing tumor cells.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced that the company has commenced enrollment in a Phase 2 clinical trial of IMO-8400, an investigational TLR 7, 8 and 9 antagonist, in patients with dermatomyositis. Dermatomyositis is a rare and debilitating inflammatory muscle and skin disease associated with significant morbidity, decreased quality of life and an increased risk of premature death.
Hythiam, Inc. announced today that the results of a double-blind, placebo-controlled study on the impact of the medical component of the PROMETA® Treatment Program on alcohol dependent subjects was accepted and published in the Journal of Clinical Psychopharmacology, a leading scholarly publication in psychopharmacology that features articles reporting on clinical trials and studies.
› Verified 1 days ago